The ArteraAI Prostate Test is transforming the risk stratification landscape for treating prostate cancer. For lower-risk patients, the test results can guide patient suitability for active surveillance. For intermediate-risk patients, there’s a predictive test result to determine if ST-ADT is beneficial. For high-risk patients, there’s insights to guide abiraterone usage along with radiation therapy and LT-ADT. And for recurrent patients after prostatectomy, the test can help guide ADT use alongside salvage radiation.
Listen to Drs. Ken Nepple, Murilo de Almeida Luz, and Ben Fischer-Valuck on how they’ve incorporated the test into their workflows and how it’s impacted patients in their prostate cancer care. They review real-world case examples, specifically biochemical recurrent cases post radical prostatectomy, and how the test results helped determine adjunctive ADT usage.
Fill out the form below to view the recording…
